Please use this identifier to cite or link to this item:
|Title:||Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness|
|Author:||Guerreiro Castro, S|
Systemic Lupus Erythematosus
|Citation:||Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85|
|Abstract:||Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.|
|Appears in Collections:||MED - Artigos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.